Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer
- PMID: 22186789
- PMCID: PMC3293620
- DOI: 10.1038/mt.2011.269
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer
Abstract
We performed a phase I trial of FANG vaccine, an autologous tumor-based product incorporating a plasmid encoding granulocyte-macrophage colony-stimulating factor (GMCSF) and a novel bifunctional short hairpin RNAi (bi-shRNAi) targeting furin convertase, thereby downregulating endogenous immunosuppressive transforming growth factors (TGF) β1 and β2. Patients with advanced cancer received up to 12 monthly intradermal injections of FANG vaccine (1 × 10(7) or 2.5 × 10(7) cells/ml injection). GMCSF, TGFβ1, TGFβ2, and furin proteins were quantified by enzyme-linked immunosorbent assay (ELISA). Safety and response were monitored. Vaccine manufacturing was successful in 42 of 46 patients of whom 27 received ≥1 vaccine. There were no treatment-related serious adverse events. Most common grade 1, 2 adverse events included local induration (n = 14) and local erythema (n = 11) at injection site. Post-transfection mean product expression GMCSF increased from 7.3 to 1,108 pg/10(6) cells/ml. Mean TGFβ1 and β2 effective target knockdown was 93.5 and 92.5% from baseline, respectively. Positive enzyme-linked immunospot (ELISPOT) response at month 4 was demonstrated in 9 of 18 patients serially assessed and correlated with survival duration from time of treatment (P = 0.025). Neither dose-adverse event nor dose-response relationship was noted. In conclusion, FANG vaccine was safe and elicited an immune response correlating with prolonged survival. Phase II assessment is justified.
Figures
Similar articles
-
Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver.Oncology. 2014;87(1):21-9. doi: 10.1159/000360993. Epub 2014 Jun 25. Oncology. 2014. PMID: 24968881 Clinical Trial.
-
Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine.Clin Cancer Res. 2011 Jan 1;17(1):183-92. doi: 10.1158/1078-0432.CCR-10-2195. Clin Cancer Res. 2011. PMID: 21208907 Clinical Trial.
-
Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine.Gene Ther. 2013 Sep;20(9):875-9. doi: 10.1038/gt.2013.9. Epub 2013 Mar 7. Gene Ther. 2013. PMID: 23466552
-
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy.Future Oncol. 2024;20(29):2149-2164. doi: 10.1080/14796694.2024.2376518. Epub 2024 Aug 5. Future Oncol. 2024. PMID: 39101448 Free PMC article. Review.
-
GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer.J Control Release. 2003 Aug 28;91(1-2):225-31. doi: 10.1016/s0168-3659(03)00210-4. J Control Release. 2003. PMID: 12932654 Review.
Cited by
-
Overcoming TGFβ-mediated immune evasion in cancer.Nat Rev Cancer. 2022 Jan;22(1):25-44. doi: 10.1038/s41568-021-00413-6. Epub 2021 Oct 20. Nat Rev Cancer. 2022. PMID: 34671117 Review.
-
Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials.Front Oncol. 2022 Oct 21;12:945867. doi: 10.3389/fonc.2022.945867. eCollection 2022. Front Oncol. 2022. PMID: 36338747 Free PMC article.
-
Novel Immunotherapies for Osteosarcoma.Front Oncol. 2022 Apr 1;12:830546. doi: 10.3389/fonc.2022.830546. eCollection 2022. Front Oncol. 2022. PMID: 35433427 Free PMC article. Review.
-
Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy.Cancer Gene Ther. 2022 Jul;29(7):993-1000. doi: 10.1038/s41417-021-00400-x. Epub 2021 Nov 16. Cancer Gene Ther. 2022. PMID: 34785763 Free PMC article. Clinical Trial.
-
Design of Effective Primary MicroRNA Mimics With Different Basal Stem Conformations.Mol Ther Nucleic Acids. 2016 Jan 12;5(1):e278. doi: 10.1038/mtna.2015.53. Mol Ther Nucleic Acids. 2016. PMID: 26756196 Free PMC article.
References
-
- Smyth MJ, Dunn GP., and, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1–50. - PubMed
-
- Schreiber RD, Old LJ., and, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565–1570. - PubMed
-
- Alard P, Clark SL., and, Kosiewicz MM. Deletion, but not anergy, is involved in TGF-beta-treated antigen-presenting cell-induced tolerance. Int Immunol. 2003;15:945–953. - PubMed
-
- Wahl SM, Swisher J, McCartney-Francis N., and, Chen W. TGF-beta: the perpetrator of immune suppression by regulatory T cells and suicidal T cells. J Leukoc Biol. 2004;76:15–24. - PubMed
-
- Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5:263–274. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources